CHICAGO — Comprehensive prescription drug monitoring program mandates appeared associated with a moderate reduction in the number of opioid analgesics dispensed to people dying of cancer, according to study results.
Reductions were two to three times higher among non-Hispanic Black and Asian/Pacific Islander decedents than non-Hispanic white decedents, findings presented at ASCO Annual Meeting showed.
“Prescription drug monitoring program (PDMP) mandates should explicitly exempt cancer-related pain,” Yuhua Bao, MD, professor of population health sciences at Weill Cornell